For example, the expression of CD9 significantly decreased in metastatic breast cancer, colonic cancer and prostate cancer cells than in primary tumor cells, while the high expression of CD9 could weaken migration ability of various kinds of tumor cells [18], [19]. This evidence concerns the gene CD9 and Familial prostate cancer.